On Thursday 30 November 2017 Novartis announced that the New England Journal of Medicine (NEJM) has published positive results from the pivotal Phase III STRIVE study, which showed 50 per cent of people using erenumab 140 mg for six months instead of placebo saw the amount of migraine attacks experienced over a month reduced by at least half.
Arlene Wilkie, Chief Executive of The Migraine Trust said:
‘We are pleased to see the latest positive data results from the on going study of this preventative treatment which could lead to significant improvements in the quality of life for many people with migraine. Migraine is a chronic painful condition cited by the latest report from The Lancet’s Global Burden of disease report (October 2017) as the second leading cause of years lived with a disability. Migraine is often misunderstood by those who do not experience it and this development could prove life-changing for many who live with migraine.’
Original Content Source